We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker Consistently Gains From NANO & New Strategic Buyouts
Read MoreHide Full Article
On Mar 25, we issued an updated research report on Bruker Corporation (BRKR - Free Report) . The stock carries a Zacks Rank #2 (Buy).
Bruker continues to witness a strong year-over-year rise in organic revenues. We look forward to the company's Scientific Instruments segment that has been performing well, driven by strong results from NANO and CALID groups.
Acquisitions like Anasys and JPK (completed last April and last July, respectively) contributed to the Bruker Nano Surfaces group’s top line. The Nano Surfaces and Nano-analysis revenues increased in 2018 with substantial organic growth, supplemented by these two buyouts. The year 2019 is expected to be no exception. Notably, in mid-December 2018, NANO closed the transaction of Alicona Imaging, a provider of optical metrology products for lab and production applications, which will be accretive to the group's results in 2019.
Bruker is progressing well with three strategic buyouts, mirroring a majority interest in both Hain Diagnostics and Mestrelab along with Alicona Imaging acquisition. Further, the company made a progress in advancing the proteomics and phenomics initiative with the rollout of timsTOF Pro and the gradual uptake of NMR phenomics.
On the flip side, over the past month, shares of Bruker have underperformed the industry. The stock has inched up 0.3% compared with the industry’s rise of 3.1%.
The company’s core BEST group in 2018 was up modestly over 2017. This was driven by a pickup in superconductor demand in the back half of 2018 and the timing of some big science projects that offset the declines the company saw in the first half. Further, Bruker’s core BioSpin division faces a fierce competition from the companies offering magnetic resonance spectrometers. Through 2018, this business has been relentlessly sluggish. Notably, a competitive landscape and macroeconomic woes persistently pose challenges to the company.
Stryker's long-term earnings growth rate is projected to be 10%.
Penumbra’s long-term earnings growth rate is predicted to be 20.9%.
Varian’s long-term earnings growth rate is forecast at 8%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Bruker Consistently Gains From NANO & New Strategic Buyouts
On Mar 25, we issued an updated research report on Bruker Corporation (BRKR - Free Report) . The stock carries a Zacks Rank #2 (Buy).
Bruker continues to witness a strong year-over-year rise in organic revenues. We look forward to the company's Scientific Instruments segment that has been performing well, driven by strong results from NANO and CALID groups.
Acquisitions like Anasys and JPK (completed last April and last July, respectively) contributed to the Bruker Nano Surfaces group’s top line. The Nano Surfaces and Nano-analysis revenues increased in 2018 with substantial organic growth, supplemented by these two buyouts. The year 2019 is expected to be no exception. Notably, in mid-December 2018, NANO closed the transaction of Alicona Imaging, a provider of optical metrology products for lab and production applications, which will be accretive to the group's results in 2019.
Bruker Corporation Price
Bruker Corporation Price | Bruker Corporation Quote
Bruker is progressing well with three strategic buyouts, mirroring a majority interest in both Hain Diagnostics and Mestrelab along with Alicona Imaging acquisition. Further, the company made a progress in advancing the proteomics and phenomics initiative with the rollout of timsTOF Pro and the gradual uptake of NMR phenomics.
On the flip side, over the past month, shares of Bruker have underperformed the industry. The stock has inched up 0.3% compared with the industry’s rise of 3.1%.
The company’s core BEST group in 2018 was up modestly over 2017. This was driven by a pickup in superconductor demand in the back half of 2018 and the timing of some big science projects that offset the declines the company saw in the first half. Further, Bruker’s core BioSpin division faces a fierce competition from the companies offering magnetic resonance spectrometers. Through 2018, this business has been relentlessly sluggish. Notably, a competitive landscape and macroeconomic woes persistently pose challenges to the company.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Penumbra, Inc (PEN - Free Report) and Varian Medical Systems, Inc , each stock currently carrying the same solid Zacks Rank of 2 as Bruker. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker's long-term earnings growth rate is projected to be 10%.
Penumbra’s long-term earnings growth rate is predicted to be 20.9%.
Varian’s long-term earnings growth rate is forecast at 8%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>